Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Army Seeks Characterization Services for Burkholderia, Plague

by Global Biodefense Staff
July 22, 2014

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) is seeking firms capable of providing research services to profile the host response to pathogens that occur through intracellular and intercellular signaling mechanisms to support ongoing countermeasures research.

The required intracellular tasks are to use the entire workflow of the Reverse Phase Protein Microarray (RPMA) technology to provide and analyze the phosphoproteomic profiling of target host proteins that are significantly affected during infection with geographical isolates of Burkholderia species, and to perform the functional characterization of select host targets that are identified through RPMA.

Additionally, functional characterizations of select Yersinia pestis host targets identified through RPMA analysis will be required.

For examination of intercellular signaling, the contractor is required to conduct a comprehensive analysis of the mechanisms of exosome-based intercellular communication during infection with Y. pestis and also other biodefense agents using different methodologies, including RPAM and mass spectrometry (MS) analysis.

The contractor shall perform the required services in 4 phases:

  1. Preparation of samples with assistance from USAMRIID personnel and performing QC.
  2. Performance of proteomic analyses using RPMA and MS methods.
  3. Bioinformatic analysis of the collected data, verification of the discovered hits, and identification of protein networks of interest.
  4. Performing follow-up functional assays to test the host targets of interest for future countermeasure approaches. For the RPMA data, a total of six target genes, or the number selected in consultation with USAMRIID, will be analyzed.

USAMRIID will provide samples for analysis and perform the necessary in vitro and cell-based assays when required. USAMRIID will also perform microscopy, immunological, and other assays to verify the integrity and efficacy of the samples.

USAMRIID will provide recommendations on all 4 phases of the work that are indicated above, including data analysis and the development of appropriate functional assays to analyze identified targets, to ensure that the final findings will meet mission needs for future development of effective and FDA-licensable countermeasures.

The Government anticipates a single contract with a Period of Performance of one year-long base period plus two option years. Upon review of industry response to this Sources Sought Notice, the Government will determine whether a set-aside acquisition in lieu of full and open competition is in the Government’s best interest.

Capability statements may be submitted under Solicitation Number: W81XWH-14-R-0071. Responses are due by July 31, 2014

Tags: BurkholderiaY. pestis

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC